Cargando…

Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Show Differences in Autoantibody Signatures Based on Disease Activity

Systemic juvenile idiopathic arthritis (SJIA) is a severe rheumatic disease in children. It is a subgroup of juvenile idiopathic arthritis (JIA; MIM #604302), which is the most common rheumatic disease in children. The diagnosis of SJIA often comes with a significant delay, and the classification be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krainer, Julie, Hendling, Michaela, Siebenhandl, Sandra, Fuehner, Sabrina, Kessel, Christoph, Verweyen, Emely, Vierlinger, Klemens, Foell, Dirk, Schönthaler, Silvia, Weinhäusel, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527260/ https://www.ncbi.nlm.nih.gov/pubmed/37759792 http://dx.doi.org/10.3390/biom13091392

Ejemplares similares

Prevalence of autoantibodies in patients with juvenile idiopathic arthritis: results from the German inception cohort ICON-JIA
por: Schulz, Caroline, et al.
Publicado: (2022)

Systemic autoinflammatory diseases
por: Krainer, Julie, et al.
Publicado: (2020)

Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
por: Kumar, Sharath, et al.
Publicado: (2012)

An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)
por: Bullement, Ash, et al.
Publicado: (2021)

Functional Analysis of Autoantibody Signatures in Rheumatoid Arthritis
por: Milchram, Lisa, et al.
Publicado: (2022)

EPIC-TABSAT: analysis tool for targeted bisulfite sequencing experiments and array-based methylation studies
por: Krainer, Julie, et al.
Publicado: (2019)

Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks?
por: Gohar, Faekah, et al.
Publicado: (2016)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
por: De Benedetti, F, et al.
Publicado: (2011)

Antibody Profiling and In Silico Functional Analysis of Differentially Reactive Antibody Signatures of Glioblastomas and Meningiomas
por: Milchram, Lisa, et al.
Publicado: (2023)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy
por: Nirmala, N, et al.
Publicado: (2013)

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)
por: De Benedetti, F, et al.
Publicado: (2013)

PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
por: Quartier, P, et al.
Publicado: (2013)

Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis
por: Verweyen, Emely L., et al.
Publicado: (2023)

Prolonged Fever in a Pediatric Patient: A Case of Systemic Juvenile Idiopathic Arthritis (sJIA) Complicated by Macrophage Activation Syndrome (MAS)
por: Cortes, Marianne, et al.
Publicado: (2023)

P02-029 - CAPS or SJIA
por: Alekseeva, E, et al.
Publicado: (2013)

IL-18 production upon s100 stimulation is reduced in active sJIA patients compared to sJIA patients in remission and healthy controls
por: Haar, Nienke Ter, et al.
Publicado: (2014)

Synergistic Signaling of TLR and IFNα/β Facilitates Escape of IL-18 Expression from Endotoxin Tolerance
por: Verweyen, Emely, et al.
Publicado: (2020)

A survey of tools for the analysis of quantitative PCR (qPCR) data
por: Pabinger, Stephan, et al.
Publicado: (2014)

Trajectories of disease courses in the inception cohort of newly diagnosed patients with JIA (ICON-JIA): the potential of serum biomarkers at baseline
por: Ganeva, Margarita, et al.
Publicado: (2021)

Diagnostic Performance of Plasma DNA Methylation Profiles in Lung Cancer, Pulmonary Fibrosis and COPD
por: Wielscher, Matthias, et al.
Publicado: (2015)

The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies
por: Rider, Lisa G., et al.
Publicado: (2013)

Autoantibodies in the Pathogenesis, Diagnosis, and Prognosis of Juvenile Idiopathic Arthritis
por: Mahmud, Shawn A., et al.
Publicado: (2019)

Autoantibodies as diagnostic markers and potential drivers of inflammation in ulcerative colitis
por: Jodeleit, Henrika, et al.
Publicado: (2020)

S100A12 as diagnostic tool in the differential diagnosis of sJIA associated MAS vs. hereditary or acquired HLH
por: Holzinger, D, et al.
Publicado: (2015)

PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial
por: Malattia, C, et al.
Publicado: (2013)

Full pathogen characterisation: species identification including the detection of virulence factors and antibiotic resistance genes via multiplex DNA-assays
por: Wolff, Noa, et al.
Publicado: (2021)

Mutations of familial hemophagocytic lymphohistiocytosis (FHL) related genes and abnormalities of cytotoxicity function tests in patients with macrophage activation syndrome (MAS) occurring in systemic juvenile idiopathic arthritis (sJIA)
por: Bracaglia, Claudia, et al.
Publicado: (2014)

Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model
por: Bracaglia, Claudia, et al.
Publicado: (2014)

Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study
por: Tappeiner, Christoph, et al.
Publicado: (2018)

Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial
por: Gerss, Joachim, et al.
Publicado: (2022)

PReS-FINAL-2040: Outcome of macrophage activation syndrom (MAS) in systemic juvenile idiopatic arthritis (SJIA) in non biologic treated patient
por: Lazarevic, DS, et al.
Publicado: (2013)

Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study
por: Heiligenhaus, Arnd, et al.
Publicado: (2019)

Outcome of repeat dosing of sJIA patients with tocilizumab in one UK centre
por: Livermore, P, et al.
Publicado: (2008)

Anti-keratin and anti-cyclic citrullinated peptide autoantibodies in patients with juvenile idiopathic arthritis
por: Vavrinec, J, et al.
Publicado: (2002)

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
por: Brachat, A, et al.
Publicado: (2015)

Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still’s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity
por: Kudela, Holger, et al.
Publicado: (2019)

The Significance of Autoantibodies in Juvenile Dermatomyositis
por: Kwiatkowska, Dominika, et al.
Publicado: (2021)

Tumour auto-antibody screening: performance of protein microarrays using SEREX derived antigens
por: Stempfer, René, et al.
Publicado: (2010)

Effect of Adalimumab on Refractory Arthritis in Juvenile Idiopathic Inflammatory Myopathy with Anti-MDA5 Autoantibody
por: Miyamae, Takako, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0r19u975ml61iuuv2n4rm9okus